Finance

Beta
Lists
TRAX:NASDAQ
First Tracks Biotherapeutics Inc
$19.30
+3.82%
(+0.71) 1D
$19.80
+2.59% (+0.50)
After hours
Closed: Jul 2, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for TRAX...
Open
$18.60
High
$19.46
Low
$18.19
Mkt. cap
673.42M
Avg. vol.
606.06K
Volume
559.25K
52-wk high
$25.58
52-wk low
$14.88
Shares outstanding
34.89M
No. of employees
104
Open
$18.60
High
$19.46
Low
$18.19
Mkt. cap
673.42M
Avg. vol.
606.06K
Volume
559.25K
52-wk high
$25.58
52-wk low
$14.88
Shares outstanding
34.89M
No. of employees
104
News stories
From sources across the web
About First Tracks Biotherapeutics Inc
CEO-
Employees104
Founded2019
Headquarters-
SectorBiotechnology
Websitefirsttracksbio.com
Analyst ratings
Based on 7 analysts giving stock ratings to TRAX in the past 3 months
Strong buy
Buy
7
Hold
0
Sell
0
12-month forecast
Based on 7 Wall Street analysts offering 12 month price targets for TRAX in the last 3 months.
Highest
Current $19.30
$54.00 (+179.79%)
Average
$37.14 (+92.44%)
Lowest
$30.00 (+55.44%)
Analyst
Recommendation
Action
Price target
Projected
Date
Derek Archila
Wells Fargo
Buy
Initiated
$30.00
+55.4%
06/08/2026
Anupam Rama
J.P. Morgan
Buy
Maintained
$30.00
+55.4%
05/22/2026
Martin Fan
Wedbush
Buy
Maintained
$30.00
+55.4%
05/15/2026
Emily Bodnar
H.C. Wainwright
Buy
Reiterated
$30.00
+55.4%
05/15/2026
Etzer Darout
Barclays
Buy
Maintained
$40.00
+107.3%
05/15/2026
Yasmeen Rahimi
Piper Sandler
Buy
Initiated
$54.00
+179.8%
05/04/2026
David Risinger
Leerink Partners
Buy
Initiated
$46.00
+138.3%
04/24/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Mar 2025
Mar 2026
Revenue
-
-
Cost of goods sold
-
-
Cost of revenue
-
-
Research and development expenses
41.46M
33.96M
Total research and development expenses
-
-
Selling, general, and admin expenses
9.82M
18.86M
Operating expense
51.28M
52.81M
Total operating expenses
51.28M
52.81M
Operating income
-51.28M
-52.81M
Other non operating income
-7.00K
-1.00K
EBT including unusual items
-47.20M
-50.48M
EBT excluding unusual items
-47.20M
-50.48M
Income tax expense
-
-
Effective tax rate
-
-
Other operating expenses
-
-
Net income
-47.20M
-50.48M
Net profit margin
-
-
Earnings per share
-
-
Interest and investment income
4.09M
2.33M
Interest expense
-
-
Net interest expenses
4.09M
2.33M
Depreciation and amortization charges
-
-
EBITDA
-51.13M
-52.69M
Gain or loss from assets sale
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer